drugset / Trial / NCT00189280

Aldara for the Treatment of Large and/or Multiple sBCC

NCT00189280

Phase 3 Completed 111 enrolled MEDA Pharma GmbH & Co. KG
Non-randomizedSingle-groupOpen-labelTreatment

Summary

BCC is the most common form of skin cancer. Current treatment is often surgery but this can be limited by the number of lesions, their location the age of the patient or the potential cosmetic outcome. The purpose of this study is to evaluate the effectiveness of imiquimod, on a non surgical treatment, in subjects with multiple of large sBCCs.

Timeline

Start
2003-05
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 5 %

Indications